It's Never 2 Late Taps Video Game Development & Healthcare Technology Expert Matt Miller to Lead Product Development

It's Never 2 Late®, the leader in providing person-centered digital engagement, content and technology solutions for seniors, announced the expansion of its leadership team with the addition of Matt Miller as Vice President of Product Development. This addition underscores iN2L's commitment to providing personalized engagement solutions that include interactive multimedia, cognitive based gamification and adaptive devices to keep seniors active, connected and engaged.

For nearly five years, Miller was a development director for Electronic Arts (EA), one of the world's largest gaming companies by revenue. EA pioneered the home computer games industry and currently develops and publishes games under several labels. As program manager at EA SPORTS, Miller was accountable for rapid, on-time product delivery of the EA SPORTS MMA video game involving a staff of 80 development managers, programmers, artists and designers. Matt was also responsible for overseeing several other titles during his time at EA including Madden NFL and Tiger Woods PGA.   

"At iN2L, we work hard to make a difference in people's lives by developing an extensive library of programs, content and video games designed for elders with a wide range of physical and cognitive abilities, most of whom have never used a computer," said CEO Tom Bang. "We are thrilled that Matt Miller shares our mission and has joined us to bring our technology innovation to new heights."

Most recently, Miller served as the Advisory Board Company's managing director of healthcare technology product development. There he was responsible for 16 SaaS Products with $290M+ annual contract value, including analytics and advisory solutions designed to improve healthcare organizations' business and clinical performance. Miller successfully increased overall visibility, predictability and efficiency of all products.

"I am thrilled to be joining a company that's focused on making a meaningful impact in the lives of elders," said Miller. "Exercise is just as important to the brain as the rest of the body. I look forward to applying my expertise in gaming, analytics, and healthcare product development to create innovative solutions that analyze and measure cognitive function in order to deliver individualized experiences that help seniors' minds stay sharp."

Miller gained additional hands-on healthcare technology knowledge and expertise during his tenure at PhDx Systems, Naval Hospital Pensacola, Naval Hospital Roosevelt Roads and Naval Medical Center San Diego.

Miller completed an M.B.A. in Information Technology Management from Touro University International in Los Alamitos, Calif.

About It's Never 2 Late  
It's Never 2 Late® (iN2L) is an award-winning developer of digital engagement technology for senior living community residents, with over 2,500 installations in the United States and Canada. The company's picture-based, touchscreen interface provides easy connectivity to the Internet, including video chat and e-mail, regardless of users' physical and cognitive abilities. Additionally, iN2L's media library offers more than 4,000 social, educational and spiritual content options, as well as games developed specifically for individuals with cognitive challenges. Residents can realize the full benefits of interactive technology while reducing isolation, increasing cognitive stimulation and enhancing independence. For more information about iN2L, visit www.in2l.com. Access case studies, research, testimonials, and our blog on our Ideas & Insights page. Follow us on Facebook, Twitter and LinkedIn.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.